Drug Database
IN

indapamide (indapamide, Douglas)

✓ Approved

Douglas Pharmaceuticals Limited · SLC12A3 · Small Molecule

What is indapamide?

indapamide is a small molecule developed by Douglas Pharmaceuticals Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namesindapamide, Douglas
CompanyDouglas Pharmaceuticals Limited
Drug ClassSmall Molecule
Molecular TargetSLC12A3
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Douglas Pharmaceuticals Limited

Mechanism of Action

Molecular Targets

indapamide acts on 1 molecular target:

SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

indapamide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved

Related Research Articles

PubMedInternational journal of hypertension2026-07-15

Real-World Effectiveness and Safety of Ramipril/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records.

Mogielnicki Mariusz M, Płaszczyca Marian M, Leary Andrew A, Piechaczek Mateusz M et al.

This study aimed to evaluate the patient characteristics, effectiveness, safety, adherence, and persistence of ramipril/indapamide (R/I) free combination therapy in patients with essential hypertension inadequately controlled with monotherapy. This retrospective observational cohort study used anonymized UK primary care electronic health records from IQVIA's Medical Research Database (IMRD), incorporating "The Health Improvement Network" (THIN), a Cegedim Database. Adults with essential hypertension who switched from ramipril or indapamide monotherapy to R/I between database inception and January 1, 2021, were enrolled. Outcomes included changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), proportions achieving BP < 140/90 mmHg or SBP ≥ 20 mmHg/DBP ≥ 10 mmHg decrease, proportion of days covered (PDC), persistence, and adverse events (AEs) over 12 months. A total of 1089 patients met inclusion criteria (mean age 63.5 years; 55.6% female). Mean baseline BP on monotherapy was 156.0/89.1 mmHg. Over 12 months, mean SBP decreased by 18.7 mmHg and DBP by 8.9 mmHg (both p < 0.001); 54.3% of patients achieved BP < 140/90 mmHg, and 61.6% met the predefined BP decrease threshold. A dose-response relationship was observed for BP outcomes. Mean PDC was 92.4% at 3 months and 86.2% at 12 months; persistence was 87.7% and 81.5%, respectively. The most frequent AE was cough (10.38%); gout occurred in 0.73%, exclusively in indapamide-naïve patients. The outcomes remained consistent across sensitivity and subgroup analyses. Switching from ramipril or indapamide monotherapy to their free combination was associated with clinically meaningful BP decreases, high adherence and persistence, and a favorable safety profile in routine practice. These findings are consistent with current therapeutic guidelines that endorse its use in essential hypertension management.

PMID 42453630
Read full article →
PubMedFrontiers in pharmacology2026-07-14

Impact of the national centralized volume-based procurement policy on antihypertensive drug procurement, price, and volume in Guangxi: an interrupted time series analysis of procurement data.

Liang Shuang S, Zhang Shuang S, Li Ling L, Luo Jing J et al.

The impact of China's national centralized volume-based procurement (NVBP) policy on antihypertensive drug procurement in underdeveloped, multi-ethnic regions remains understudied. This study evaluated changes in procurement prices, volumes, and costs for four antihypertensive drugs following the second NVBP batch in Guangxi, an economically disadvantaged region in southwestern China. Monthly procurement data for four NVBP antihypertensive drugs (Olmesartan Medoxomil, Candesartan Cilexetil, Terazosin Hydrochloride, and Indapamide) were collected from January 2019 to April 2021, covering 16 months before and 12 months after policy implementation (May 1, 2020). Interrupted time series (ITS) analysis with Newey-West standard errors was used to assess immediate and sustained changes in log-transformed defined daily doses (DDDs) and defined daily dose costs (DDDc). Sensitivity analyses examined robustness to a January 2021 procurement spike. Following policy implementation, the average unit price of the four drugs decreased by 81.52%, and median DDDc dropped by 96.88% to 99.78%. ITS models showed significant immediate increases in DDDs for all four drugs (all p < 0.001), but no significant sustained long-term trend (all β 3 not significant, p > 0.05). A sharp DDDs spike occurred in January 2021, followed by a decline. Sensitivity analyses confirmed that the spike did not affect the direction or significance of the main estimates. The second NVBP batch was associated with substantial and sustained reductions in procurement prices and costs for these four antihypertensive drugs in Guangxi. However, procurement volumes showed marked volatility without stable long-term growth. These findings, based on procurement records rather than patient-level data, suggest that price reductions alone may not ensure consistent procurement patterns. Strengthening supply chain resilience and aligning procurement schedules with clinical demand may support more stable drug supply in disadvantaged regions.

PMID 42445249
Read full article →
PubMedThe Journal of urology2026-06-30

Urinary Supersaturation in a Randomized Trial Among Individuals with Recurrent Nephrolithiasis Comparing Empiric Versus Selective Preventive Therapy: The URINE Trial.

Hsi Ryan S RS, Lee Aaron X AX, Koyama Tatsuki T, Widmer Annaliese A et al.

To compare a strategy using testing to guide treatment, also known as selective therapy, with a strategy of initiating interventions without testing, termed empiric therapy, on urinary supersaturation of calcium oxalate and calcium phosphate. In this single-center trial, adult individuals with recurrent idiopathic calcium stone disease were randomized to either an empiric or selective strategy. Participants received 24-hour urine testing at baseline, 4 weeks, and 8 weeks. Treatment in the empiric arm comprised dietary and fluid counseling and pharmacologic treatment with indapamide and potassium citrate irrespective of 24-hour urine results. For the selective arm, diet, and pharmacologic treatments, which included indapamide, potassium citrate, and/or allopurinol, were tailored based on urine testing at baseline and 4 weeks. The primary outcome was urinary supersaturation of calcium oxalate and calcium phosphate at 8 weeks. The analytic sample included 56 participants (mean [SD] age, 44.5 [13.2] years; 30 women [54%]), with 29 randomized to the empiric and 27 to the selective groups. At week 8, there were no significant differences comparing the empiric and selective arms with respect to mean [SD] urinary supersaturation of calcium oxalate (4.7 [2.9] vs 5.0 [2.9], respectively, P = .81) or calcium phosphate (1.3 [0.9] vs 1.4 [1.1], respectively, P = .58). Similarly, there were no significant differences at 8 weeks in urine volume and pH or in excretion of calcium, oxalate, citrate, uric acid, and sodium. In this short-term trial among individuals at high risk for stone recurrence, there was no statistically significant difference in the urinary stone risk comparing an empiric vs selective strategy for kidney stone prevention.

PMID 42378339
Read full article →
PubMedPakistan journal of medical sciences2026-06-08

Drug-Induced Hyponatremia Surveillance: A disproportionality analysis based on FAERs database.

Xi Xin X, Bai Zhanfeng Z, Liu Songqing S, Dong Jie J

Mining the risk signals of drug-induced hyponatremia by the United States Food and Drug Administration adverse event reporting system (FAERS) database, to provide reference for clinical safe medication. Adverse drug events related to drug induced hyponatremia were analyzed by disproportionality analysis using the FAERS data between 2004 to 2023 were downloaded (https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html). A total of 1,306 drugs with identifiable risk signals were associated with Hyponatremia. Five drugs demonstrated the highest cases counts: furosemide (n=1,560), hydrochlorothiazide (n=1049), sertraline (n=899), omeprazole(n=864), citalopram (n=738). The pharmacovigilance analysis identified five substances exhibiting the strongest association signals: indapamide (ROR=91.46, 95% CI 83.38-100.32), hydrochlorothiazide (ROR=46.79, 95% CI 43.96-49.81), desmopressin (ROR=34.08, 95% CI 31.49-36.89), oxcarbazepine (ROR=24.47, 95% CI 22.72-26.37), and furosemide (ROR=24.11, 95% CI 22.91-25.37). Nivolumab (36.92%), bortezomib (30.58%), and zoledronic (29.36%) exhibited the highest proportional occurrence of target adverse events involving fatal or life-threatening outcomes. Additionally, clinical information about Drug-induced hyponatremia is absent from the Summary of Product Characteristics of 10 drugs in our study. We provide a list of drugs with risk signals for Hyponatremia. In clinical practice, it is helpful to identify the culprit drug early, and prevent it from further aggravation into a serious condition.

PMID 42257098
Read full article →
PubMedDrug design, development and therapy2026-05-21

Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.

Youn Jong-Chan JC, Lee So-Young SY, Yu Cheol Woong CW, Sung Ki-Chul KC et al.

Effective blood pressure (BP) control in hypertension frequently requires combination therapy, particularly in patients whose BP is inadequately controlled by monotherapy. This study evaluated the efficacy and safety of fimasartan (FMS) and indapamide (IND) sustained release (SR) combination therapy. In this randomized, double-blind, phase III trial, patients with hypertension who remained uncontrolled after a 4-week run-in with FMS 30 mg, were randomized to FMS 30 mg/IND SR 1.5 mg or FMS 30 mg, followed by forced titration to FMS 60 mg/IND SR 1.5 mg or FMS 60 mg after 4 weeks. The primary endpoint was the change in sitting systolic BP (SiSBP) at week 8. Secondary endpoints included changes in sitting diastolic BP (SiDBP), BP control rates, response rates, and safety outcomes. Two hundred forty-eight patients were randomized (FMS/IND SR, n=126; FMS, n=122). At week 8, the least square mean reduction in SiSBP was greater with FMS/IND SR than with FMS (-17.9 vs -7.4 mmHg, P<0.0001). Significant improvements were also observed for SiSBP at week 4, SiDBP at week 4 and 8, and BP control rates and response rates. The safety profile was comparable between groups, with no significant differences in adverse events, including patients aged 65 years and older. FMS/IND SR combination therapy demonstrated superior antihypertensive efficacy, rapid BP control, and comparable safety to FMS monotherapy. This regimen may serve as an effective therapeutic option, particularly in elderly or high-risk hypertensive patients. https://www.clinicaltrials.gov, NCT05878561.

PMID 42163997
Read full article →
PubMedActa crystallographica. Section E, Crystallographic communications2026-05-08

An analogue of indapamide: crystal structure and Hirshfeld surface analysis of 3-chloro-4-(N,N-diethynylsulfamo-yl)-N-(2-meth-yl-indolin-1-yl)benzamide.

Ramli Youssef Y, Al Garadi Wedad W, Essassi El Mokhtar EM, Kalonji Mubengayi Camille C et al.

The title mol-ecule, C22H20ClN3O3S, adopts a shallow cup-shaped conformation with the chloro-benzamide portion as the bottom. A puckering analysis of the five-membered ring indicates an envelope conformation. In the crystal, helical chains along the a-axis direction are formed by N-H⋯O hydrogen bonds reinforced by C-H⋯π(ring) and weak π-stacking inter-actions. No directed inter-actions between chains appear to exist. A Hirshfeld surface analysis was performed.

PMID 42099419
Read full article →

+1368 more articles available with a free account

Sign up free to view all articles →

Ask about indapamide